163 related articles for article (PubMed ID: 37565582)
21. microRNA-378a-3p regulates the progression of hepatocellular carcinoma by regulating PD-L1 and STAT3.
Li Y; Zhou T; Cheng X; Li D; Zhao M; Zheng WV
Bioengineered; 2022 Mar; 13(3):4730-4743. PubMed ID: 35184646
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA-200b is a potential biomarker of the expression of PD-L1 in patients with lung cancer.
Katakura S; Kobayashi N; Hashimoto H; Kamimaki C; Tanaka K; Kubo S; Nakashima K; Teranishi S; Manabe S; Watanabe K; Horita N; Hara Y; Yamamoto M; Kudo M; Piao H; Kaneko T
Thorac Cancer; 2020 Oct; 11(10):2975-2982. PubMed ID: 32893980
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer.
Kim H; Kwon HJ; Park SY; Park Y; Park E; Chung JH
PLoS One; 2018; 13(6):e0198634. PubMed ID: 29856861
[TBL] [Abstract][Full Text] [Related]
24. Let-7a/cMyc/CCAT1/miR-17-5p Circuit Re-sensitizes Atezolizumab Resistance in Triple Negative Breast Cancer through Modulating PD-L1.
Selem NA; Nafae H; Manie T; Youness RA; Gad MZ
Pathol Res Pract; 2023 Aug; 248():154579. PubMed ID: 37301086
[TBL] [Abstract][Full Text] [Related]
25. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
[No Abstract] [Full Text] [Related]
26. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
Kao SC; Cheng YY; Williams M; Kirschner MB; Madore J; Lum T; Sarun KH; Linton A; McCaughan B; Klebe S; van Zandwijk N; Scolyer RA; Boyer MJ; Cooper WA; Reid G
J Thorac Oncol; 2017 Sep; 12(9):1421-1433. PubMed ID: 28629895
[TBL] [Abstract][Full Text] [Related]
27. A Novel Epigenetic Strategy to Concurrently Block Immune Checkpoints PD-1/PD-L1 and CD155/TIGIT in Hepatocellular Carcinoma.
Assal RA; Elemam NM; Mekky RY; Attia AA; Soliman AH; Gomaa AI; Efthimiadou EK; Braoudaki M; Fahmy SA; Youness RA
Transl Oncol; 2024 Jul; 45():101961. PubMed ID: 38631259
[TBL] [Abstract][Full Text] [Related]
28. MicroRNA-519d-3p antagonizes osteosarcoma resistance against cisplatin by targeting PD-L1.
Wang J; Zhang Z; Qiu C; Wang J
Mol Carcinog; 2022 Mar; 61(3):322-333. PubMed ID: 34780678
[TBL] [Abstract][Full Text] [Related]
29. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
30. MiRNA expression profiling in adenocarcinoma and squamous cell lung carcinoma reveals both common and specific deregulated microRNAs.
Petkova V; Marinova D; Kyurkchiyan S; Stancheva G; Mekov E; Kachakova-Yordanova D; Slavova Y; Kostadinov D; Mitev V; Kaneva R
Medicine (Baltimore); 2022 Aug; 101(33):e30027. PubMed ID: 35984198
[TBL] [Abstract][Full Text] [Related]
31. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
Smazynski J; Hamilton PT; Thornton S; Milne K; Wouters MCA; Webb JR; Nelson BH
Gynecol Oncol; 2020 Jul; 158(1):167-177. PubMed ID: 32446718
[TBL] [Abstract][Full Text] [Related]
32. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
[TBL] [Abstract][Full Text] [Related]
33. Transcriptomic studies provide insights into the tumor suppressive role of miR-146a-5p in non-small cell lung cancer (NSCLC) cells.
Iacona JR; Monteleone NJ; Lemenze AD; Cornett AL; Lutz CS
RNA Biol; 2019 Dec; 16(12):1721-1732. PubMed ID: 31425002
[TBL] [Abstract][Full Text] [Related]
34. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
35. CD155 expression impairs anti-PD1 therapy response in non-small cell lung cancer.
Jiang C; Qu X; Ma L; Yi L; Cheng X; Gao X; Wang J; Che N; Zhang H; Zhang S
Clin Exp Immunol; 2022 Jun; 208(2):220-232. PubMed ID: 35262683
[TBL] [Abstract][Full Text] [Related]
36. A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery.
Shadbad MA; Safaei S; Brunetti O; Derakhshani A; Lotfinejad P; Mokhtarzadeh A; Hemmat N; Racanelli V; Solimando AG; Argentiero A; Silvestris N; Baradaran B
Genes (Basel); 2021 Aug; 12(8):. PubMed ID: 34440380
[TBL] [Abstract][Full Text] [Related]
37. Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas.
Yoon CJ; Chang MS; Kim DH; Kim W; Koo BK; Yun SC; Kim SH; Kim YS; Woo JH
Gastric Cancer; 2020 Sep; 23(5):780-795. PubMed ID: 32206940
[TBL] [Abstract][Full Text] [Related]
38. Thalidomide suppresses angiogenesis and immune evasion via lncRNA FGD5-AS1/miR-454-3p/ZEB1 axis-mediated VEGFA expression and PD-1/PD-L1 checkpoint in NSCLC.
Xia Y; Wang WC; Shen WH; Xu K; Hu YY; Han GH; Liu YB
Chem Biol Interact; 2021 Nov; 349():109652. PubMed ID: 34520751
[TBL] [Abstract][Full Text] [Related]
39. Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.
Zhang P; Ma Y; Lv C; Huang M; Li M; Dong B; Liu X; An G; Zhang W; Zhang J; Zhang L; Zhang S; Yang Y
Cancer Sci; 2016 Nov; 107(11):1563-1571. PubMed ID: 27581532
[TBL] [Abstract][Full Text] [Related]
40. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
